Academic-industry partnership aims to lower the cost of cultivated meat – University of Toronto

When the University of TorontosMichael Gartongot a call from Myo Palate a company that is producing meat without raising whole animals he knew it was the opportunity hed been waiting for.

My research has always been focused on health care and medical applications, says Garton, an assistant professor in the Institute of Biomedical Engineering in the Faculty of Applied Science & Engineering.

But environmental issues are something I really care about something we all care about. Given the impact that agriculture has on the environment, I knew this would be a great way to make a difference.

Myo Palate is looking tap the synthetic biology expertise of Garton and his team in an effort to reduce the cost of growing muscle cells. The collaborationis funded by a grant provided jointly by Genome Ontario and the Canadian Food Innovation Network.

This is an exciting opportunity to collaborate with Dr. Garton and utilize cutting-edge synthetic biology techniques to reduce the cost of growing muscle cells, says Frank Yu, co-founder of Myo Palate.

While our initial products will not contain genetic modifications, we think that this will be a game changer for the future.

Gartonscurrent medical researchinvolvesdesigning customized stem cells, derived from a patients own tissues, that could be used to treat certain diseases or conditions.

For example, one challenge we are interested in is neurological diseasessuch as multiple sclerosis or ALS, which are caused or amplified by chronic inflammation of nerve tissue, says Garton.

We can take stem cells from a patient and program them to specifically detect chronic inflammation and to release anti-inflammatory molecules in response. We could then re-implant those cells back into the body.

Because the anti-inflammatory molecules are released only where and when they are needed, this approach known asex vivogene therapy could reduce the side effects associated with treatment via traditional drugs.

Using this knowledge to create cultivated meat that is, animal cells grown outside a living animal may not seem like an intuitive leap to make, but Garton says that there are plenty of parallels.

In our work, we face the challenge of getting our stem cells to grow and differentiate into the types of tissues we want to make, he says.

Producers of cultivated meat will be doing much of the same thing. And because their cells will be consumed as food, rather than implanted into a patient, there are fewer obstacles in the overall process, which in a way makes it slightly easier.

But the challenges of creating cultivated meat go well beyond whether or not it is technically possible economics are also critically important. Cultivated meat is not yet cost-competitive with raising whole animals, which is one of the major factors limiting its widespread adoption.

Unless we can get the cost down, its just not going to fly, says Garton. What were hoping is that our expertise in synthetic biology can reduce or even remove the need for some of the more costly inputs.

One example is growth factors, which are specialized biochemicals that signal what kind of environment a given cell is growing in. Their presence or absence determines what type of tissue a stem cell will grow into: for example, skin, nerves or muscle.

In the case of cultivated meat, the goal is typically to produce myocytes, or large muscle cells. While growth factors that result in this type of tissue can be readily purchased, their relatively high cost is a major hurdle to producing cultivated meat at a competitive price.

Garton and his team hope that their research can result in stem cells that require lower amounts of these growth factors, or even none at all.

Were testing lots of different ways of approaching this challenge, and were also automating the process so we can do it in a high-throughput way, says Garton.

Were developing machine learning methods that can sort through the data to find out whats working and whats not, and what will most likely be successful in the next iteration.

Garton says he is excited about the opportunity to make an impact in a fast-growing field.

Its going to be a very long time before we have a stem cell that automatically grows into a real muscle in the lab with minimal inputs, he says.But in terms of putting the foundational pieces and core building blocks in place to achieve that, I think were going to be able to deliver some real insights relatively quickly.

Read the original:
Academic-industry partnership aims to lower the cost of cultivated meat - University of Toronto

Does Chemotherapy Have Cognitive and Emotional Side Effects? – Healthline

Chemotherapy has transformed cancer care, but its benefits come with side effects. Chemo brain is the name some people give to the brain fog and fuzziness that can result from these lifesaving treatments.

Chemotherapy works by destroying fast-reproducing cancer cells. But it can kill other healthy cells along the way, including certain brain cells. The destruction of brain cells can impact your emotional state and ability to think, leading to memory and concentration problems, among other concerns.

This article will explore what types of cognitive and emotional changes you might expect from chemotherapy, what factors increase your risk for these symptoms, and what you can do to treat them.

Various emotional and cognitive symptoms can occur during chemotherapy, and they should be categorized separately. Even though they both apply to your brain and can be considered mental side effects, emotion and cognition are different.

Cognition refers broadly to the intellectual processes of absorbing, analyzing, and using information. Emotions are our feelings and responses to experiences, environments, and relationships. For example, trouble focusing is a cognitive side effect, whereas irritability is an emotional one.

Lets go over some of the most common chemotherapy side effects in both categories.

Cognitive changes are usually the most noticeable impacting daily functioning, work or school performance, and personal relationships.

Confusion or delirium is the most common of these symptoms, affecting roughly 57 to 85 percent of people undergoing chemotherapy, compared to 15 to 30 percent of people hospitalized for other medical reasons.

Cognitive changes can look different depending on the individual but commonly include:

In addition to chemo, other factors can contribute to emotional stress as part of a cancer diagnosis. The emotional impacts of chemo can look like shifts in mood, depression or anxiety. Personality changes are common, too.

These can be linked to chemotherapy treatments, the disease process, and coping with a cancer diagnosis.

Learn more about the emotional impacts of a cancer diagnosis and cancer treatment.

There are several reasons why chemotherapy can impact your mental and emotional health.

One reason is that chemo medications cross the blood-brain barrier, causing inflammation. Brain shrinkage, or a loss of neurons, has been observed as a result of both cancer and chemotherapy.

Cognitive changes can also be heightened by complications of cancer treatment or other medical conditions. Chronic pain and lack of sleep or appetite from chemotherapy treatments can have profound negative life impacts.

This can affect your energy and strength levels, making it hard to focus or regulate your emotions.

Cancers spread to the brain can also directly affect cognitive and emotional functioning. This can be separate from, or in addition to, chemo.

While chemotherapy aims to slow or stop the spread of cancer, increased changes in mental status and cognition can also be signs of metastasis, or that the cancer is spreading.

Your doctor may also want to rule out intolerances or reactions to your chemotherapy treatment.

Treating cancer requires an individualized and multidisciplinary approach. Often, a rehabilitation plan is involved in helping you cope with or heal from the effects of chemotherapy and other intensive treatments, including any surgeries.

Your doctor may want to adjust your chemotherapy regimen depending on your side effects.

Cognitive rehabilitation is sometimes included in a chemotherapy plan and offers activities or exercises to help keep your mind sharp and focused during treatment.

The American Cancer Society suggests that exercise and meditation can go a long way in reducing the mental toll of chemotherapy and other cancer treatments.

Also, talk therapy, including cognitive behavioral therapy (CBT), may help you process the complex emotions arising from a cancer diagnosis and treatment.

Talk therapies can help you develop coping techniques that may help you manage fatigue, confusion, and any depression or anxiety you are experiencing due to chemotherapy.

There are particular cancer and chemotherapy medications that can increase the chances of confusion, delirium, and other cognitive changes in some people. Your doctor should review any risks of a potential treatment option with you when designing your chemo regimen.

Consider coming to your appointment prepared with questions about what risk of physical and mental impacts chemo may cause. Ensure your doctor knows all medications you are currently taking to avoid adverse reactions.

If you choose to move forward with treatment, your doctor may be able to help you find ways to preserve your thinking abilities should chemo affect them, or at the very least learn to cope with the changes.

There are certain risk factors that may increase your chance of experiencing mental side effects during chemotherapy.

Besides taking specific medications or having brain cancer, this can include having:

Chemotherapy can effectively manage cancer and bring about remission. But the medications for chemotherapy are strong and highly toxic to other cells and systems in your body. This treatment can cause unpleasant physical, mental, and emotional symptoms.

The physical effects of chemotherapy like nausea and hair loss are well-known, but substantial mental and cognitive changes can also happen with this therapy. Chemo brain refers to the fatigue, confusion, and overall brain fog some people experience.

Talk with your doctor about the specific risks versus benefits for your type of cancer, stage, and prescribed chemotherapy regimen. Your medical team should be able to help you with therapies and strategies that can help you cope with the emotional and cognitive toll of cancer and chemotherapy.

The rest is here:
Does Chemotherapy Have Cognitive and Emotional Side Effects? - Healthline

Crowdfunder launched to pay for life-changing treatment abroad for Brora mum battling MS issues: ‘If you can help me get a chance of a new life, I…

Residents in Sutherland are being urged to support a crowdfunder to meet the cost of private treatment abroad for a local woman diagnosed with a potentially life-threatening illness.

A fundraising drive has been launched in the hope of sending 41-year-old Kirsteen Mackay, a Durness native now living in Brora, to Mexico for treatment which she is unable to access on the NHS.

Within hours of the crowdfunder going live this week, it had reached 20 per cent of its 57,000 target.

On her social media page, Ms Mackay, who is experiencing a complication linked to multiple sclerosis, said: The last few years have been a struggle for me and this last year has been the worst as I have had failed treatments with awful side effects.

I just want to thank those who have helped me and continue to do so, as I would not have made it this far without you.

I know money is tight for everyone, but if you can help me get a chance of a new life, I will be forever grateful.

The caring, generous and fun-loving mum, who has a six-year-old son Ruaraidh and who runs Kirsteens Kollection, a decor service for all occasions, was diagnosed in 2018 with relapsing-remitting multiple sclerosis (RRMS).

Jade McAlea, who set up the crowdfunder said: Kirsteens RRMS is very active and medication is crucial to keeping symptoms or the progression of symptoms under control.

But Ms Mackay was recently dealt a devastating blow when she was told she had tested positive for John Cunningham virus (JC).

The virus is common and usually harmless - in most people it is dormant and does not directly cause health problems. However it can trigger a life-threatening condition called multifocal leukoencephalopathy (PML).

A few of the medications that doctors use to treat MS can reactivate the dormant virus and lead to PML.

This means that treatment for RRMS has been reduced to one option, which can be used for a year, said Ms McAlea. Unfortunately this treatment is also linked to patients being in a high-risk category for developing PML.

The NHS has been wonderful so far in supporting Kirsteen with effective treatment for her RRMS diagnosis, but with this most recent development of JC, the treatment option and timeline is simply time she does not have to spare due to the risk of symptoms exacerbating..

Her most hopeful outcome is to undergo treatment which is available privately in Mexico, but the cost of this treatment means it is an option out of reach. That is where we believe people can make the lifesaving difference.

The procedure Ms Mackay hopes to undergo at Clinica Ruiz in Puebla, is Haematopoietic Stem Cell Transplantation (HSTC), an intense chemotherapy treatment where the patients own stem cells are used to reboot their immune system.

Ms Mackay is not eligible for HSTC on the NHS because she is not a wheelchair user, her family said. The treatment is not available privately in Scotland and there are long waiting lists to have it privately in England.

Ms McAlea continued: We have every faith in our community that we can all come together at such a devastating time for Kirsteen and her family.

No help is too big or small and with all your support, we can provide Kirsteen with the hope of a healthy, happy future.

Click here to donate.

Read the original post:
Crowdfunder launched to pay for life-changing treatment abroad for Brora mum battling MS issues: 'If you can help me get a chance of a new life, I...

Updates in the Treatment of HER2+ mBC from ASCO 2022 – OncLive

Vijayakrishna Gadi, MD, PhD: I would say that, in all of this HER2 disease, sadly if you have HER2-postivie breast cancer, although weve done a tremendous job extending the lives of those patients, ultimately the majority of those patients still die. We cant rest on our laurels, and weve got to keep innovating in this area. There are many, many new molecules and entities that are being considered, and Im excited to test those. Weve heard about a number of them at this 2022 ASCO [American Society of Clinical Oncology Annual] Meeting, and obviously in its early days, and we hope that those will come in.

The other emphasis or way to look at it is, now that we have all these tools, what can we put together in a safe manner that could still be effective for our patients? Ill highlight a few trials in this regard. One is looking at combining T-DM1 [trastuzumab emtansine] with tucatinib; the so-called HER2CLIMB-02 study [NCT03975647]. Thats a trial thats ongoing. We hope that itll accrue quickly, and then well have answers, but heres a generally well-tolerated antibody-drug conjugate being combined with tucatinib, which has the CNS [central nervous system]-penetrating ability. You can see where Im going with this with covering our bases above the neck but also below the neck. That could be one option. If its successful, its a randomized phase 3 trial, so it could be a new standard of care depending on what we learn from that.

Theres a DESTINY-Breast trial looking in a phase 2 setting at patients with CNS metastases and the combination of tucatinib. That study is still looking at safety initially, and then hopefully we will be able to expand out to efficacy cohorts. Itll be a smaller study, but it may give us a signal that then we can formally test in a larger randomized control trial. Thats another option. Then lastly, [we are] looking at combinations with drugs like tucatinib and conventional things like chemotherapy: trastuzumab and pertuzumab. Although its not from the metastatic setting, when we try to do that in the I-SPY2 trial [NCT01042379] in the preoperative setting, that was actually too toxic. It was effective, but it was too toxic and should not be pursued at this time, so weve got to go back to the drawing board on that one. Its not all wins. We are going to look at these combinations, but certainly, with the tools we have, we may be able to push the needle quite a bit by just combining them. The adage is, If you cant beat them, join them, so thats what were seeing in this space.

At2022 ASCO, a standing ovation talk claimed there is a new standard of care, which was the DESTINY-Breast04 trial [NCT0373402].. To refresh everybodys memory just in case, DESTINY-Breast04 was a trial that looked at patients with HER2-low diseaseIm going to talk about the definition of HER2-low in a minuteand using trastuzumab deruxtecan vs physicians choice chemotherapy options. In that trial, [there was a] running away nice separation of the curves for this HER2-low population favoring the trastuzumab deruxtecan. Fortunately, [there were] not a lot of new emergent [adverse] effects or toxicities that make us take pause in this. [They were] very familiar in terms of toxicities and were in many cases favorable compared to chemotherapy. [It is] very easy to say, Yeah, this could be a new standard of care.

Now Im Monday-morning quarterbacking on this molecule in this study. First off, what is HER2-low? We know that some cancers, when they express HER2 strongly, we call it HER2+. Those are cancers where the driver is the HER2 gene. Those are cancers that we can target with all our conventional therapies that weve had access to: trastuzumab, pertuzumab, tucatinib, neratinib, and all these molecules become relevant. For these, HER2, IHC [immunohistochemistry] 2-positive and below, this is not a driver. Its a target of convenience. The expression is necessary to get the antibody-drug conjugate to the location, internalize the chemotherapy, and then kill the cancer cell. Fortunately, with trastuzumab deruxtecan, you have this wonderful thing called bystander killing. The chemotherapy leaks out and kills the neighboring cells as well. Even if you have low or heterogeneous expression of the HER2 target as a target of convenience, its localizing the chemotherapy to where we need it to be, and that chemotherapy is very potent. That has now formally been tested in a randomized controlled [phase] 3 trial and that hypothesis is true. This is an effective molecule for that disease space.

As we try to integrate this, a lot of these patients have hormone receptorpositive disease. I suspect were going to continue to tackle that because those therapies are well tolerated compared to chemotherapies and even antibody-drug conjugates. Once those stop working for our patients, its very easy to think how well be reaching for trastuzumab deruxtecan for those patients. Within that trial, they also studied what we call triple-negative disease thats HER2-low. For those patients, there are now a couple of options. We have sacituzumab govitecan, which is formally evaluated in a robust dataset and [has been] shown to benefit those patients, but we also have this very active molecule, trastuzumab deruxtecan. If you notice how Im saying these words, govitecan [and] deruxtecan, they end in the same terminal 5 letters. These are all Topo1 inhibitors, so there may be cross-resistance. Our ability to use these drugs one after the other isnt assumed. We have to test that formally to see if thats even possible. I think, in the triple-negative space, [its] a little murky. For those HER2-low [cases], you have a couple of options, and for those that dont make HER2 at any level, the so-called HER2-0 [cases], I think sacituzumab govitecan might be the choice for those patients.

Thank you very much for listening to my ramblings about HER2-positive metastatic breast cancer. Its a rapidly changing field. If you took boards just a few years ago, youve go5t to know a lot going forward to make sure you do well on the boards in the future. Fortunately, for our patients, this innovation is really making an impact for them, so thank you to the patients whove also participated on these studies to help the patients coming down the pipe.

Transcript has been edited for clarity.

See the article here:
Updates in the Treatment of HER2+ mBC from ASCO 2022 - OncLive

Global Adrenoleukodystrophy Treatment Market Trends, Growth, Opportunities and Forecast to 2029 Designer Women – Designer Women

Theadrenoleukodystrophy treatment marketis expected to witness market growth at a rate of 10.25% in the forecast period of 2022 to 2029. Data Bridge Market Research report on adrenoleukodystrophy treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the markets growth. The rise in the prevalence of chronic diseases globally is escalating the growth of adrenoleukodystrophy treatment market.

Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addisons disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.

Get Sample PDF of the Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adrenoleukodystrophy-treatment-market

This adrenoleukodystrophy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info adrenoleukodystrophy treatment market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Adrenoleukodystrophy Treatment Market Scope and Market Size

The adrenoleukodystrophy treatment market is segmented on the basis of types, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

To get more insights into the market analysis, browse the research report summary @- https://www.databridgemarketresearch.com/reports/global-adrenoleukodystrophy-treatment-market

Adrenoleukodystrophy Treatment Market Country Level Analysis

The adrenoleukodystrophy treatment market is analyzed and market size information is provided by country, types, treatment, route of administration, end-users and distribution channel as referenced above. The countries covered in the global adrenoleukodystrophy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the adrenoleukodystrophy treatment market due to the well-established healthcare infrastructure and presence of key market players within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the rise in awareness about rare diseases in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Adrenoleukodystrophy Treatment Market Share Analysis

The adrenoleukodystrophy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related adrenoleukodystrophy treatment market.

Some of the major players operating in the adrenoleukodystrophy treatment market report are bluebird bio, Inc., Orpheris, Inc., MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer Inc., Amgen Inc., AstraZeneca, Abbott, agtc, ReceptoPharm, Inc., The Myelin Project, SOM Biotech SL, Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt. Ltd., Magenta Therapeutics, NeuroVia, Inc., Novartis AG, CELGENE CORPORATION, Jazz Pharmaceuticals, Inc., and Sanofi among others.

Browse Complete TOC athttps://www.databridgemarketresearch.com/toc/?dbmr=global-adrenoleukodystrophy-treatment-market

Related reports:

Allogenic Stem Cell Therapy Market Industry Size, Shares, Trends and Growth Prospectshttps://www.databridgemarketresearch.com/reports/global-allogenic-stem-cell-therapy-market

Cancer Stem Cell Therapy Market Industry Size, Shares, Trends and Growth Prospectshttps://www.databridgemarketresearch.com/reports/global-cancer-stem-cell-therapy-market

North America Stem Cell Therapy Market Industry Size, Shares, Trends and Growth Prospectshttps://www.databridgemarketresearch.com/reports/north-america-stem-cell-therapy-market

Europe Stem Cell Therapy Market Industry Size, Shares, Trends and Growth Prospectshttps://www.databridgemarketresearch.com/reports/europe-stem-cell-therapy-market

Asia Pacific Stem Cell Therapy Market Industry Size, Shares, Trends and Growth Prospectshttps://www.databridgemarketresearch.com/reports/asia-pacific-stem-cell-therapy-market

Middle East and Africa Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlookhttps://www.databridgemarketresearch.com/reports/middle-east-and-africa-stem-cell-therapy-market

Asia-Pacific Drug-Device Combination Market Size, Shares, Trends and Industry Growth Outlookhttps://www.databridgemarketresearch.com/reports/global-drug-device-combination-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working across different industries.We have served over 40% of Fortune 500 companies globally and have a network of over 5,000 clients worldwide.Data Bridge knows how to create satisfied customers who rely on our services and rely on our hard work with certainty.We are pleased with our glorious 99.9% customer satisfaction rating.

Contact us:-

Data Bridge Market Research

USA: +1 888 387 2818

UK: +44 208 089 1725

Hong-Kong : +852 8192 7475

E-mail :-corporatesales@databridgemarketresearch.com

Read more:
Global Adrenoleukodystrophy Treatment Market Trends, Growth, Opportunities and Forecast to 2029 Designer Women - Designer Women

SCUBE3 as a treatment for hair loss and alopecia – Open Access Government

Researchers from the University of California have discovered that a signalling molecule called SCUBE3 potently stimulates hair growth and may offer therapeutic treatment for androgenetic alopecia, a common form of hair loss in both women and men.

The precise mechanism uses dermal papilla cells, which play a pivotal role in controlling hair growth.

These cells specialise in signal-making fibroblasts at the bottom of each hair follicle, which promotes new hair growth.

The production of activating molecules by the dermal papilla cells is critical for efficient hair growth in mice and humans. In people with androgenetic alopecia, dermal papilla cells malfunction, greatly reducing the normally abundant activating molecules.

The genetic basis of the activating molecules involved has been previously poorly understood, so the researchers used a mouse model with hyperactivated dermal papilla cells and excessive hair to facilitate more discoveries about hair growth regulation.

After the researchers microinjected SCUBE3 into mouse skin, where human scalp follicles had been transplanted, new growth began in both the dormant human and surrounding mouse follicles.

Maksim Plikus, Ph.D., UCI professor of developmental & cell biology, said: At different times during the hair follicle life cycle, the very same dermal papilla cells can send signals that either keep follicles dormant or trigger new hair growth.

We revealed that the SCUBE3 signalling molecule, which dermal papilla cells produce naturally, is the messenger used to tell the neighbouring hair stem cells to start dividing, which heralds the onset of new hair growth.

Co-first author Yingzi Liu, a UCI postdoctoral researcher in developmental & cell biology, added: Studying this mouse model permitted us to identify SCUBE3 as the previously unknown signalling molecule that can drive excessive hair growth.

Currently, there are two medications on the market, finasteride and minoxidil, which have been approved by the Food and Drug Administration for androgenetic alopecia in the USA.

Finasteride is only approved for use in men, but both drugs are not universally effective and need to be taken daily to maintain their clinical effect. SCUBE3 could be an alternative to these medications in the future.

co-first author Christian Guerrero-Juarez, a UCI postdoctoral researcher in mathematics, said: These experiments provide proof-of-principle data that SCUBE3 or derived molecules can be a promising therapeutic for hair loss.

Plikus finalised: There is a strong need for new, effective hair loss medicines, and naturally occurring compounds that are normally used by the dermal papilla cells present ideal next-generation candidates for treatment. Our test in the human hair transplant model validates the preclinical potential of SCUBE3.

Read more:
SCUBE3 as a treatment for hair loss and alopecia - Open Access Government

Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D – Yahoo…

WARREN, N.J., July 07, 2022--(BUSINESS WIRE)--Tevogen Bio, a late stage clinical biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced the appointment of preeminent oncologist Neal Flomenberg, M.D. as Chief Scientific Officer (CSO) and Global Head of Research and Development. Dr. Flomenberg will lead the companys diverse and rapidly advancing research and development initiatives of its highly adaptable precision T cell product pipeline in oncology, neurology, and virology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005531/en/

Acclaimed oncologist and immunotherapy expert, Neal Flomenberg, M.D. joins Tevogen Bio as Chief Scientific Officer and Global Head of R&D (Photo: Business Wire)

Most recently, Dr. Flomenberg served as Professor and Chairman of the Department of Medical Oncology and Deputy Director of Sidney Kimmel Cancer Center of Thomas Jefferson University & Hospital. Under his leadership, Jeffersons Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program. At Jefferson, Dr. Flomenberg also served as Director of the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Program.

Throughout his more than forty-year career, Dr. Flomenberg has maintained a longstanding interest in the immunogenetics and immunology of stem cell transplantation, with the goal of making transplantation safer and more widely available. As Chairman of Tevogens Scientific Advisory Board, he helped advance Tevogens lead investigational product, TVGN-489, through proof-of-concept clinical trial for treatment of high-risk COVID-19 patients. Trial enrollment is currently nearing completion.

Story continues

In his new capacity at Tevogen, Dr. Flomenberg will serve as member of the executive team and lead companys ambitious R&D initiatives, allowing for further advancement of its next generation precision T cell technology platforms. Dr. Flomenberg and his leadership team will operate out of Tevogens R&D Center located in Philadelphias Wanamaker building.

"There is no better person than Neal to lead the advancement of Tevogens highly promising genetically unmodified T cell technology platforms, which we believe will pave the way for the next era of personalized T cell therapeutics for large patient populations through convenience and affordability for the very first time," said Tevogen CEO Ryan Saadi, M.D., M.P.H. "A lifelong student of science, Neals compassionate nature, brilliant mind, and unwavering passion to innovate leading-edge medicines for the good of humanity are just a few of the characteristics that make him the ideal leader to realize the fullest potential of our R&D initiatives."

"I am thrilled to serve in this new role at Tevogen, a truly patient-centric company designed to achieve commercial success through its advanced science and efficient business model which ensure affordability. I have dedicated my career to increasing our understanding of blood cancers and the infections which plague these and other patient groups as well as the cellular immunologic approaches which might be used to address these problems," said Dr. Flomenberg. "Tevogens proprietary approach allows cellular immunotherapeutics to be developed with unprecedented specificity and precision while remaining affordable and broadly applicable. Applications range from acute viral infections such as COVID-19, to longer term consequences of infections such as Long-COVID and Multiple Sclerosis, to viral-induced and non-viral induced cancers," he added.

Dr. Flomenberg has been the recipient of numerous awards including: The Simon Gratz Award for Research Most Likely to influence Patient Care (2003), The Leukemia Lymphoma Society Contributions to Mankind Award (2006), The Pennsylvania State University Outstanding Science Alumnus Award (2006), Inaugural recipient of the Philadelphia Chapter of the Leukemia Lymphoma Societys Lifetime Achievement Award (2018), Thomas Jefferson Universitys Alumnus of the Year Award (2019), and Jeffersons Deans Lifetime Distinguished Service Award (2022).He received a Bachelor of Science degree from Penn State University and earned a Doctor of Medicine degree from Jefferson Medical College.

About Tevogens Next Generation Precision T Cell Platform

Tevogens next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses.

Tevogen is investigating its technologys potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogens goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

The companys lead product, TVGN-489, is currently in clinical trial for high-risk COVID-19 patients at Jefferson University Hospitals in Philadelphia. TVGN-489 is a highly purified, genetically unmodified, off-the-shelf, allogeneic SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product designed to detect targets spread across the entire viral genome.

Tevogen recently announced the initiation of the fourth and final dose level of its investigational T cell therapy for high-risk COVID-19 patients in the proof of concept clinical trial of TVGN-489. No dose limiting toxicities or treatment-related adverse events, including Cytokine Release Syndrome (CRS), have been observed to date in any of the dose cohorts.

About Tevogen Bio

Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogens leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio Inc (the "Company") and its business. These statements are based on managements current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the Companys control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as "may," "will," "should," "intend," "expect," "believe," "potential," "possible," or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Companys expectations and actual results, including, among others: the Companys limited operating history; uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials; risks related to regulatory review and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Companys future financial results, including the commercial potential, sales, and pricing of the Companys products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions herefrom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005531/en/

Contacts

Media: Katelyn Joyce Corporate Communications Lead T: 1 877 TEVOGEN, Ext 709 Katelyn.joyce@tevogen.com

Read more:
Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D - Yahoo...

Embryonic Stem Cells – Stem Cells and the Future of Regenerative …

Embryonic stem cells (ESCs) are found in the inner cell mass of the human blastocyst, an early stage of the developing embryo lasting from the 4th to 7th day after fertilization. In normal embryonic development, they disappear after the 7th day, and begin to form the three embryonic tissue layers. ESCs extracted from the inner cell mass during the blastocyst stage, however, can be cultured in the laboratory and under the right conditions will proliferate indefinitely. ESCs growing in this undifferentiated state retain the potential to differentiate into cells of all three embryonic tissue layers. Research involving human ESCs is at the center of the ethical debate about stem cell use and potential in regenerative medicine. Embryos from which ESCs are extracted are destroyed in the process.

Several scientific questions are important when considering the potential of stem cells for use in regenerative medicine and the policy and ethical issues that arise:

What properties of ESCs have promise for regenerative medicine?

What direct evidence supports ESCs' effective use in regenerative medicine?

What obstacles and risks are associated with the use of ESCs in regenerative medicine?

Human ESCs were successfully grown in the laboratory for the first time in 1998 (Thompson et al., 1998). Under appropriate culture conditions, ESCs have demonstrated a remarkable ability to self-renew continuously, that is, to produce more cells like themselves that are multipotent. As indicated at the workshop by Thomas Okarma and Ron McKay, ESC lines established from single cells have been demonstrated to proliferate through 300-400 population-doubling cycles. Human ESCs that have been propagated for more than 2 years also demonstrate a stable and normal complement of chromosomes, in contrast to the unstable and abnormal complement of embryonic cancer cell lines used in the past to study early stages of embryonic development. Careful monitoring of the aging ESC lines will be needed to evaluate the significance of genetic changes that are expected to occur over time.

Because human ESCs have only recently become available for research, most of what is known about ESCs comes from studies in the mouse, which, as noted in Chapter 2, cannot be presumed to provide definitive evidence of the capabilities of human cells.

Nevertheless, ESCs derived from mouse blastocysts have been studied for 2 decades and provide a critical baseline of knowledge about the biology and cultivation of these cells (Torres, 1998; Wobus and Boheler, 1999). The factors that permit the mouse ESC to continue replicating in the laboratory without differentiation and methods to trigger differentiation into different cell types that exhibit normal function have been actively explored. Among the types of cells derived from cultured mouse ESCs are fat cells, various brain and nervous system cells, insulin-producing cells of the pancreas, bone cells, hematopoietic cells, yolk sac, endothelial cells, primitive endodermal cells, and smooth and striated muscle cells, including cardiomyocytesheart muscle cells (Odorico et al., 2001).

Experience with mouse ESCs has provided clues to methods for culturing human ESCs and leading them to differentiate. Mouse ESCs will proliferate in an undifferentiated state in the presence of a biochemical called leukemia inhibitory factor (LIF), but the culture conditions required to keep human ESCs from differentiating include growing them in petri dishes on a layer of mouse embryonic fibroblasts (referred to as feeder cells) in a medium containing serum from cows. The feeder cells are inactivated, so they are not dividing and expanding, but they produce growth factors that sustain the ESCs. The mechanism of how feeder cells maintain the proliferation of undifferentiated ESCs is unknown. Such in vitro culturing presents certain theoretical hazards to the use of stem cells for regenerative medicine, such as the spread of viruses and other infectious agents not normally found in humans. When removed from feeder cells and grown in suspension (in liquid), human ESCs form aggregated balls of cells called embryonic bodies, which have been reported to give rise to a multiplicity of cell types representing all three layers of embryonic tissue development (Itskovitz-Eldor et al., 2000; Reubinoff et al., 2000; Schuldiner et al., 2000). Evidence of the differentiation in culture includes detection of the products of genes associated with different cell types and in some cases by the characteristic shapes that are peculiar to different cell types. Cells derived from human embryonic bodies include rhythmically contracting cardiomyocytes, pigmented and nonpigmented epithelial cells, and neural cells displaying an exuberant outgrowth of axons and dendrites (Odorico et al., 2001). In other experiments, cells arising from human ESCs have been reported to express genes associated with liver and pancreas function (Schuldiner et al., 2000). Human ESCs grown in coculture with mouse bone marrow stromal cells have been reported to produce colonies of human hematopoietic precursors and ultimately cells from the blood (Kaufman et al., 1999).

Further evidence of the multipotent capability of human ESCs is based on studies in an in vivo setting. Human ESCs injected into mice form a type of benign tumor called a teratoma that is made up of tissues from all three embryonic layers. The tissues that arise in the tumor are often advanced, organized, and complex, and include teeth, gut, hair follicles, skin, epithelium, muscle, bone, cartilage, lung tissue, and neural cells (Thompson et al., 1998). The experiments showed the capability of ESCs to produce a variety of tissues, but the results also highlight the complexity of the biological program of tissue development that can unfold in different biological environments. These results also emphasize the abnormal, potentially neoplastic potential of ESCs when placed into unnatural environments.

Major questions remain about the genetic or environmental factors in the body that control the fate of ESCs and about the importance of different factors during various stages of cell differentiation. Even on the basis of the limited findings, however, the ability to grow human ESCs in vitro and to have them differentiate in the laboratory makes them an important and unique tool with which to conduct the basic research that is critical for the foundation of future regenerative therapies. It has been possible, for example, to create a lineage of mouse ESCs that generate neural cell precursors (Li et al., 1998). Studies of the genes turned on and off as cells begin to differentiate, which are already under way with ESCs, will permit a better understanding of the genetic controls important in tissue differentiation (Duncan et al., 1998). In vitro studies of ESCs also provide an opportunity to explore the role of biochemicals produced in the normal cellular environment that induce stem cells to differentiate, to migrate to a site needing repair, and to assimilate into tissues (Schuldiner et al., 2000).

At the workshop, James Thomson and Thomas Okarma suggested that human ESCs will someday provide a potentially unlimited source of cells, differentiated in vitro, for transplantation therapies involving the liver, nervous system, and pancreas. Irving Weissman alluded to the possible use of ESCs to enhance the success of whole-organ transplantation. If HSCs derived from human ESCs could be successfully transplanted into the blood system of a transplant recipient (by using immunosuppressive drugs), any further implant tissue (say kidney or pancreas) developed with the same ESCs would not, in theory, be rejected by the recipient because the immune cells produced in the recipient's blood by the HSCs would see the implant tissue as self.

But that is a long way off, as Marcus Grompe noted, in as much as no one has yet demonstrated any in vivo reconstitution of an organ's function in either humans or experimental animals with cells derived from human ESCs. Moreover, ESCs in tissue culture give rise to a mixture of cell types all at once, and biochemical, tissue-culture, and molecular-biology techniques to control and limit differentiation require much further investigation.

Because human ESCs have only recently become available for research, and because public funding for such research has been limited, studies of how well ESCs or their differentiated tissues perform physiologic functions has been largely conducted with mouse models. Ron McKay described progress made in coaxing the in vitro differentiation of human ESCs into insulin-producing cells that might be useful in treating diabetes, but he also noted that studies have already been conducted with analogous mouse cells transplanted into mice that have diabetes and that partial restoration of insulin regulation was observed (Lumelsky et al., 2001). Other studies have demonstrated that mouse ESCs can be successfully transplanted into rodents that have Parkinson's disease symptoms and partially relieve these symptoms (Studer et al., 1998). Similarly, studies suggest that mouse ESCs can be transplanted into animals that have spinal-cord injuries and partially restore neural function (McDonald et al., 1999).

Those studies provide promise, but not definitive evidence, that similar treatments could be effective in humans. Human ESCs will need to be tested in primate models, such as those for Parkinson's disease and diabetes mellitus in the rhesus monkey. Methods for transplanting ESCs need to be developed, as do means of establishing whether the cells develop and function properly after transplantation. In some cases, it will be important to ensure that the transplanted cells or tissues are incorporated and positioned properly relative to existing tissues, such as in heart and neural tissue; the three-dimensional, cell-to-cell interactions will play important roles in the functioning of an organ. Other cells, like pancreatic islet cells, or hematopoietic cells, will require less complex incorporation.

Also, the large-scale propagation of human ESCs in culture will require that they can be grown without feeder cells (Odorico et al., 2001). Research is needed to elucidate the mechanisms of feeder cells in repressing differentiation and to find alternatives to them, at the same time eliminating the potential that an animal virus from the feeder cells might be transferred to the ESCs.

Finally, it was noted earlier that the chromosomes of human ESCs have been shown to be stable in tissue culture. This does not mean however, that ESC lines will not be subject to the random mutations that affect all cell lines as they age. In cells from humans and other animals, approximately one mutation occurs every time a cell divides. A cell that has divided 200 times in culture therefore can be expected to harbor approximately 200 different mutations (Kunkel and Bebeneck, 2000). So far, there have been no studies published about the changes that may have occurred in existing stem cell lines. Vigilant monitoring of the integrity of existing cell lines is essential to allow understanding of the impact of long-term culture, and new stem cell lines may need to be developed in the future.

In addition to demonstrating the functional effectiveness of ESC transplants, it is necessary to identify and minimize, or eliminate, the risks that ESCs might pose. Two identifiable risks are tumor formation and immune rejection. As noted earlier, human ESCs injected into mice can produce a benign tumor made up of diverse tissues; this response is believed to be related to the multipotency of the undifferentiated cells in an in vivo environment. However, in a small number of short-term studies in mice, human ESCs that have been allowed to begin the process of differentiation before transplantation have not resulted in significant tumor formation (Odorico et al., 2001). Obviously, this is a critical problem to understand and control.

It is too early to tell, therefore, whether it will be appropriate to use human ESCs directly in regenerative medicine. A great deal obviously must be elucidated about how the body controls the differentiation of stem cells, and this has yet to be reliably reproduced in vitro. Also, the behavior of ESCs implanted in a specific organ has not been well studied. It might someday be possible to add growth factors with a transplant to stimulate the production of a particular cell type or multiple cell types. Inducer tissues that interact with stem cells might be cotransplanted with ESCs to achieve a similar result. Those possibilities are still in experimental investigation.

In another respect, the possible problems associated with ESC transplantation are common to all transplantation, such as the risk of infection and the risk of tissue rejection. As discussed in Chapter 2, rejection is a serious obstacle to successful transplantation of stem cells and tissues derived from them. It has been suggested that ESCs provoke less of an immune reaction than a whole-organ transplant, but it is unclear whether that will be true of the regenerated tissues derived from ESCs. Some types of cells (such as dendritic cells, immune system cells, and vascular endothelial cells) carry more of the histocompatibility antigens that provoke immune reactions than other cells. Those types are present in the tissues of whole organs; they connect an organ with the bloodstream and nervous system. However, tissue derived in vitro from ESCs, such as liver tissue, would not contain such cells and therefore would theoretically trigger a milder immune response; this assumes that techniques for controlling differentiation of ESCs will be available. In addition, the liver cells likely would not be devoid of all surface antigens, and so, in the absence of other techniques to reduce transplant rejection, the use of immunosuppressive drugs will still have to be used, with attendant risks of infection and toxicity.

Although difficult to conceive, the creation of a very large number of ESC lines might be one way to obtain a diversity of cells that could theoretically increase the chances of matching the histocompatibility antigens of a transplant recipient. It has also been suggested that ESCs could be made less reactive by using genetic engineering to eliminate or introduce the presence of surface antigens on them (Odorico, 2001). An exact genetic match between a transplant recipient and tissue generated from ESCs could also, in theory, be achieved by using somatic cell nuclear transfer to create histocompatible ESCs (). Cells created with this technique would overcome the problem of immune rejection. However, it might to not be appropriate to transplant such cells in a person with a genetically based disease, since the cells would carry the same genetic information. In any case, an understanding of how to prevent rejection of transplanted cells is fundamental to their becoming useful for regenerative medicine and represents one of the greatest challenges for research in this field.

Somatic Cell Nuclear Transfer (SCNT)

Visit link:
Embryonic Stem Cells - Stem Cells and the Future of Regenerative ...

Human embryonic stem cells: Derivation, culture, and differentiation: A …

The ectoderm derivatives include external ectoderm, neural crest, and neural tube. These structures give rise to cells of the epidermis, external sense organs, and the peripheral and central nervous system (Gilbert, 2006).

Generating functional neurons from hESC with the aim of treating neurodegenerative diseases is the subject of intensive investigation. Shortly after derivation of the first hESC lines, Reubinoff et al. (2000) described isolation of expandable neural progenitor cells from hESC that had been cultivated for four to seven weeks at a high density in vitro. The authors illustrated that the neuroepithelium contained areas of differentiating hESC colonies, identified by expression of the embryonic polysialylated neural cell adhesion molecule (PSA-NCAM), and had distinct morphological features. These areas were mechanically dissected and expanded as neural aggregates or spheres in serum-free media. Neural induction was achieved by plating the spheres on coverslips coated with poly-D-lysine and laminin, which resulted in emergence of cells expressing the neuronal markers -tubulin and microtubule-associated protein 2 (MAP2). They also identified a subset of the neuronal cells as being glutaminergic and GABAergic neurons, as shown by the expression of glutamate and glutamic acid decarboxylase (GAD).

Reubinoff and coworkers (2001) also optimized the expansion of hESC-derived NPC by addition of B27 supplement, human recombinant epidermal factor EGF and the mitogen bFGF. The expanded NPC were capable of differentiating into all three major neural lineages (neurons, astrocytes, oligodendrocytes) in vitro as well as in vivo. Lineage tracing studies showed that NPC grafted to the ventricles of newborn mice differentiated in a region-specific manner, according to normal developmental patterning signals. For example, neuronal differentiation was specifically detected in the olfactory bulb, where postnatal neurogenesis occurs (Reubinoff et al., 2001).

At about the same time, Zhang et al. (2001) used a different protocol with similar success in generating enriched populations of NPC from hESC. In that study, differentiating EBs were treated with insulin, transferrin, progesterone, heparin, and bFGF. Continuous exposure to bFGF led to formation of monolayers of neural tube-like rosettes that were isolated by dispase enzymatic treatment. Similar to the study by Reubinoff et al. (2001), the generated NPC were capable of generating oligodendrocytes, astrocytes, and mature neurons both in vitro and after transplantation into mice.

These observations confirming the multi-lineage differentiation potential of hESC-derived NPC, and promising indications of survival and integration of these cells in vivo, set the stage for future developments of methods for selective differentiation of different neuronal phenotypes that could potentially be used to treat several central nervous system disorders. Indeed, studies examining the signals and factors that govern the proliferation and cell fate specification of neural progenitors are accumulating rapidly.

Generation of transplantable motor neurons from hESC could have potential for treating victims of spinal cord injuries, or degenerative diseases such as amyotrophic lateral sclerosis. The first functional motor neurons originating from hESC were described by Li et al. (2005). In that study, Li and colleagues used the previously described method (Zhang et al., 2001) to generate NPC cells, which were subsequently induced to become motor neurons by addition of RA to the culture medium. Further maturation to postmitotic motorneurons was induced by the ventralizing morphogenic protein SHH. An interesting aspect of this study was the specific temporal effect of RA on motor neuron induction, in that RA could induce only early, but not late neuroectodermal cells, to differentiate into motorneurons (Li et al., 2005). This occurred through upregulation of expression of HOX genes that are involved in assigning the rostrocaudal positional identity of spinal motor neurons. The functionality of the generated motor neurons was confirmed by electrophysiological experiments and establishment of neuromuscular transmission in motorneuron-myotube co-cultures (Li et al., 2005).

In another study, directed differentiation of motor neurons was achieved by addition of RA/SHH extrinsic cues to cultures of differentiating NPC generated from hESC (Lee et al., 2007). With respect to clinical potential, transplantation of hESC-derived motor neurons in developing chick embryo spinal cord showed that these cells were capable of survival and directed axonal growth over relatively long distances (Lee et al., 2007). Nevertheless, transplantation in adult rats did not result in axonal growth to outside the CNS. It should be mentioned that, although caudal and ventral patterning was achieved by RA and SHH, the initial neural induction of hESC was obtained by co-culture with MS5 mouse stromal cells, which would preclude the use of motorneurons generated by this particular strategy for any type of human transplantation therapy (Lee et al., 2007).

In a later study by Li et al. (2008), neural induction medium containing heparin and cyclic adenosine monophosphate (cAMP) in addition to RA and SHH was successful in generating a nearly homogenous population of ventral spinal progenitor cells, with highly efficient generation of motor neurons.

Promoting remyelination for treatment of neurologic disorders caused by demyelination of motor neurons is another potential application of hESC-derived cells. One of the strategies used to promote remyelination involves transplantation of oligodendrocytes, which produce the myelin sheath of motor neurons and are essential for normal signal conduction. In 2005, Keirstead and his associates demonstrated that transplantation of hESC-derived oligodendrocyte progenitor cells (OPC) produced by glial restriction media, can lead to remyelination of motorneurons, and recovery of motor function after spinal cord injury in rats (Keirstead et al., 2005). Following further assessment of the safety concerns associated with OPC transplantation in animal models (Cloutier et al., 2006), Geron Corporation obtained FDA clearance in January 2009 to begin the first human clinical trials of hESC-derived cells in the United States (see Alper 2009). OPC were generated from the H1 hESC line under current good manufacturing practices without the use of feeder cells, in defined media containing only human recombinant proteins. The Phase I trial is designed to assess the safety of transplantation of OPC in patients with acute thoracic spinal cord injuries and will be carried out at multiple medical centers.

A number of additional studies have reported the production of multiple neuronal subtypes, including cholinergic, serotonergic, GABAergic, and dopaminergic (DA) neurons, from hESC (Erceg et al., 2008; Gerrard et al., 2005; Perrier et al., 2004; Yan et al., 2005). As previously mentioned, protocols used for neural conversion of hESC generally give rise to a mixture of neuronal phenotypes. Previous studies of neural differentiation of mouse ESC have established protocols for growth factor-mediated lineage selection and survival-promoting factors of neuronal cells (Barberi et al., 2003; Lee et al., 2000; Okabe et al., 1996). As a general strategy for obtaining selective neuronal differentiation, factors with effects on the anteroposterior (AP) or the dorsoventral (DV) neuronal patterning in combination with specific neurotrophins are used at specific stages during in vitro ESC differentiation. In a comprehensive study of neural development of mouse ESC, Barberi et al. used a stromal feeder-based differentiation system to generate early ectodermal cells (6 days co-culture) and identified various combinations of factors that govern neural and neuronal subtype specification () (Barberi et al., 2003). It should be noted that these differentiation strategies for mouse ESC cannot be directly applied to hESC without some modifications.

Neural subtype specification from neural progenitors derived from mouse ESC using various combinations of inducing factors. AA, ascorbic acid; bFGF, basic fibroblast growth factor; BDNF, brain-derived neurotrophic factor; CNTF, ciliary neurotrophic factor; EGF, epidermal growth factor; FGF4, fibroblast growth factor 4; FGF8, fibroblast growth factor 8; NT4, neurotrophin-4; PDGF, platelet-derived growth factor; RA, retinoic acid; SHH, sonic hedgehog. {Adapted from Barberi et al. (2003), [100]}.

To date, the majority of studies on neural differentiation of hESC have been focused on generation of dopamine producing neurons of the midbrain subtype, due to their potential application in cell replacement therapy for Parkinsons disease. Established protocols used to generate DA neurons include allowing spontaneous differentiation of hESC, followed by addition of DA inducing molecules, SHH and FGF8, and later neurotrophic factors, or by culturing hESC on feeder cells from animal or human origin that have the ability to direct hESC to become DA neurons.

Kawasaki and coworkers in Japan discovered in 2000 that certain mouse stromal cell lines had a neural and DA promoting effect on mouse ESC (Kawasaki et al., 2000). The authors showed that the activity of the stromal cells was not mimicked by FGF8/SHH, or Wnt signaling, previously known to be key factors in development and patterning of midbrain DA neurons. Thus, this strategy was established as a new approach to generate DA neurons and was termed stromal-derived inducing activity (SDIA).

Our group as well as others have adapted this approach to generate DA neurons from hESC. When the hESC line BG01 was cultured on the mouse stromal cells for three weeks, approximately 87% of colonies contained large numbers of TH+ cells (Zeng et al., 2004). The TH+ neurons generated by SDIA had midbrain characteristics, as determined by expression of Nurr1 and Pitx3 transcription factors that are strongly associated with midbrain DA neurons. The DA neurons were functional in vitro as confirmed by electrophysiological assessments and release of dopamine. However, the survival of TH+ neurons grafted into the striatum of parkinsonian rats was very limited. A parallel study of DA induction of hESC by Perrier and colleagues (2004), combined SDIA with SHH and FGF8 patterning molecules, ascorbic acid, and various neurotrophic factors including BDNF, GDNF, TGF-3, dcAMP and demonstrated that the yield and functional properties of TH+ neurons were highly dependent on exposure to SHH and FGF8.

Other feeder cells that possess DA-inducing activity, and that have been used to generate DA neurons from ESC, include testis-derived sertoli cells (Yue et al., 2006), meningeal cells (Hayashi 2008), and striatal or mesencepahlic astrocytes (Buytaert-Hoefen et al., 2004; Roy et al., 2006). Secreted factors produced by astrocytes have also been reported to promote neurogenesis and induction of DA neurons (Nakayama et al., 2003).

Yan and coworkers (2005) demonstrated neural and DA induction of hESC in the absence of any type of feeder cells by addition of SHH and FGF8 to EB-derived neural rosettes which were manually isolated from mixed cultures. The resulting TH+ neurons comprised 50%60% of the total neuronal population and were electrophysiologically active. Other differentiation paradigms have included addition of an NPC expansion step to this protocol in order to generate a more pure population of DA neurons (Cho et al., 2008).

Although mouse stromal cells that possess SDIA activity are considered as one of the most efficient tools for converting hESC to DA neurons, the use of animal cells would preclude any downstream clinical application due to possible transfer of xenogeneic material. To understand the molecular activity of SDIA, we further assessed the activity of stromal cells and found that stromal cell surface activity promoted hESC survival and was able to enhance overall neurogenesis, whereas soluble secreted factors provided DA lineage-specific instructions (Vazin et al., 2008). We then examined the gene expression profile of potent PA6 stromal cells as compared to that of cell lines lacking the DA-inducing effect (Vazin et al., 2009). Several soluble factors and growth-inducing proteins potentially responsible for the DA phenotype-promoting component of SDIA were identified, based on high levels of expression in potent DA-inducing PA6 cells. Testing of these factors showed that a combination of four factors, stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin-B1, termed SPIE was sufficient to induce DA neuronal differentiation from hESC. The combination of these four factors mimicked SDIA activity, providing an approach for differentiating DA neurons from hESC in a culture system that is potentially suitable for clinical applications (Vazin et al., 2009).

Transplantation of DA precursors or neuronal cells is still at the stage where survival and integration needs to be optimized, as the majority of studies focusing on neural transplantation have reported limited or no survival of DA neurons. A few studies have, however, reported more encouraging results. A study by Roy et al. (2006) transplanted hESC-derived DA progenitors induced with immortalized human fetal midbrain astrocytes in the presence of SHH and FGF8, and illustrated that about 21% of the total number of transplanted cells (5 105 cells) were TH+. Long-lasting behavioral recovery was found in animals that received cell implants. The enhanced viability of the TH+ neurons post-transplantation may have been caused by the influence of fetal midbrain astrocytes during development or specification of these neurons.

A more recent study by Chiba and colleagues (2008) has indicated that SDIA-induced DA differentiation of hESC can be improved by addition of the BMP inhibitor noggin. Importantly, the number of TH+ cells found in animals transplanted with hESC treated with noggin was five times more (average of about 500 cells/animal) than the animals that received hESC induced by SDIA alone. The enhanced in vivo viability of TH+ cells was also reflected in animal behavioral recovery.

As previously discussed, the patterning of the neural tube along its DV and AP axis is determined by specific concentrations of morphogens including SHH, BMP, FGF and RA. Other important aspects involved in regional specification of NPC are the temporal effect of these factors, as well as the duration of signaling. There is evidence indicating that NPC progressively lose their differentiation potential and can no longer be regionally specified in response to instructive patterning cues after extended in vitro culturing (Machon et al., 2005; Santa-Olalla et al., 2003).

A recent study by Elkabetz and colleagues (2008) has identified a novel population of hESC-derived neural stem cells with a unique gene expression profile, termed neural rosette cells (R-NSC), which are isolated at an earlier stage of differentiation, as compared to the previously described NPC. Forse1 was used as a marker to isolate these early rosette stage cells, which adopted an anterior forebrain characteristic in the absence of extrinsic patterning factors. In contrast to NSC, the R-NSC could be re-specified toward caudal neuronal fates including motor neurons and midbrain DA neurons by SHH/RA and SHH/FGF8 treatment, respectively. This study also illustrated the in vivo survival and phenotype maintenance of these two rosette stage-derived neuronal phenotypes.

These findings provide evidence that neuronal plasticity of NSC is highly dependent on the developmental stage and restricted to a specific time window. Selective expansion of neural stem cells that retain their ability to differentiate towards specified neurons is of great potential value. Moreover, generation of restricted NSC has clinical relevance, as such cells have been reported to have a tendency to migrate towards the site of injury and rescue degenerating neurons following implantation in animal models (Bjugstad et al., 2008; Ourednik et al., 2002).

Characterization studies of SDIA-mediated neural induction have also suggested that midbrain regional identity can only be established during early stages of ESC differentiation (Parmar and Li, 2007). In addition, it has been suggested that early exposure of FGF8, before the onset of the neural stem cell transcription factor Sox1, is necessary for generation of DA neurons with a midbrain phenotype (Yan et al., 2005). Signaling duration is also known to affect the mechanisms that underlie the patterning role of factors. For example cells are known to respond analogously to varying concentrations of SHH, or to varying duration of exposure to this factor (Dessaud et al., 2007).

See the rest here:
Human embryonic stem cells: Derivation, culture, and differentiation: A ...

Controversy Over the Use of Embryonic Stem Cells in Research Hadron

Written by Margaret Wei

Stem cells have been increasing in popularity in research in recent years due to their pluripotency. Stem cells are at first unspecialized, but have the capacity to develop into specialized cells hence their valued versatility when it comes to research. Stem cell research is used to increase understanding of how diseases occur. Researchers do this by observing how the stem cells differentiate into the specialized cells (bones, heart muscle, nerves, and other organs and tissue) to better determine how diseases and conditions develop.

Origin of Stem Cells

Several different types of stem cells are used in research: embryonic, adult, induced pluripotent, and perinatal. Embryonic stem cells originate from donated fertilized eggs in vitro fertilization clinics but never implanted in a womans uterus. Adult stem cells are derived from tissue, like bone marrow, and can be used to grow different types of specialized cells. Induced pluripotent stem cells are manipulated through genetic reprogramming to transform adult cells to stem cells, and then they can be used to replace dysfunctional cells. Perinatal stem cells come from amniotic fluid and can develop into specialized cells. In laboratories, stem cells can live and grow in special solutions in test tubes or petri dishes

Of the different types of stem cells, embryonic stem cells are the most controversial because their research consists primarily of experimentation on cells that have the potential to become a developed human. These cells are derived from embryos at a developmental stage before implantation would normally occur in the uterus. During this time, fertilization occurs in the oviduct, and over the span of the next few days, the cell divides multiple times as it travels to the uterus. At this point, the embryonic cells are undifferentiated, in other words, they do not look or act like the specialized cells of the adult, and they have the potential to become any specialized adult cell type (Yu, J. and Thomson, J.A.).

The first stage of differentiation occurs after five days, and an outer layer of cells that was supposed to become a part of the placenta separates from the inner cell mass (ICM). Because of the process of implantation, the ICM cells no longer have the potential to develop into any cell type of the body, and they are quickly depleted as they differentiate into limited types of cells. Eventually, the ICM-derived cells are fixed to be embryonic stem cells if the ICM is removed from its normal embryonic environment and cultured under appropriate conditions. These specific conditions allow the cells to proliferate and replicate, while maintaining the developmental potential to form any cell type of the body (Yu, J. and Thomson, J.A.).

The diagram above illustrates the process of obtaining embryonic stem cells.

Interactive resources for schools. (n.d.). Retrieved December 30, 2020, from https://www.abpischools.org.uk/topic/stem-cells/4

Embryonic Stem Cells in Research

Stem cells are currently used in regenerative medicine where healthy cells are generated to replace diseased cells. Scientists use embryonic stem cells to determine how specific cells can be used to regenerate and repair diseased or damaged tissues in people. Further research on stem cell regeneration would be beneficial to those who have Parkinsons disease, Alzheimers disease, heart disease, stroke, burns, cancer, etc. The potential that stem cells have to become new tissue can be used in transplant and regenerative medicine.

To ensure that drugs are safe to be used on people, researchers use stem cells to test drug effectiveness before it gets approved for drug development for cardiac toxicity testing. The stem cells that are to be tested on must be programmed to acquire properties of the type of cells targeted by the drug, but more research needs to be done about how to program cells into specific cells to produce more accurate results from the tests that would show what kind of effect the drug had on the cells (Railton, 2019).

Stem Cell Controversy

Despite the benefit of the pluripotency of embryonic stem cells, controversy arises behind how embryonic stem cells originate. Because embryonic stem cells are extracted from human embryos, many scientists question the ethics of embryonic stem cell research because it is correlated to human testing. Additionally, many disagree with testing on embryonic stem cells because the fertilized embryo has the potential to develop into a human. Concerns arise about what qualities determine humans along with the pervasive debate of what constitutes as the official beginning of human life during embryonic development.

According to certain faiths and religions, human life begins at conception, meaning that an embryo is equal to a person and it has the same rights that must be respected. As a result, the scientific process of extracting the embryonic stem cell from a blastocyst and removing the inner cell mass is amounting to murder (Lo, B., & Parham, L., 2009). This mindset is commonly correlated to the opposition of abortion and with the pro-life movement. However, a number of pro-life leaders support stem cell research using frozen embryos that remain after a woman or couple has completed infertility treatment and that they have decided not to give to another couple.

According to Senator Orrin Hatch, a former U.S. senator and a representative of the conservative party interposed the idea that, I believe that human life begins in the womb, not a Petri dish or refrigerator To me, the morality of the situation dictates that these embryos, which are routinely discarded, be used to improve and save lives. The tragedy would be in not using these embryos to save lives when the alternative is that they would be discarded.

A moderate view that others possess in terms of the morality of the embryo would be that the embryo would develop into a person later in development, well after fertilization. This view believes that a newly fertilized embryo does not constitute the same characteristics as a developed individual. However this does not always mean that they do not fully believe that embryonic stem cells are solely a clump of cells and that it is ethical for research without restriction. This does not mean that they do not agree with embryonic stem cell research, many hold a middle ground in which the embryo deserves to be perceived as a potential human being, but it is acceptable to use for certain types of research given good scientific justification, careful oversight, and informed consent from the embryo donor for research (Lo, B., & Parham, L., 2009).

Solutions to Reduce Controversy

Due to the rising controversy on this topic, The National Institutes of Health created guidelines for human stem cell research in 2009, which stated how they may be used in research. Also, to ensure that ethics are not violated, the guidelines state embryonic stem cells from embryos created by in vitro fertilization can be used only when the embryo is no longer needed.

Additionally, to reduce the controversy surrounding the idea of the potential of embryonic stem cells to develop into a human, scientists began to use pluripotent stem cells as an alternative. Since pluripotent stem cells are genetically reprogrammed to transform adult cells into stem cells, they do not have the same ethical concerns as embryonic stem cells. Therefore, genetically reprogrammed pluripotent stem cells do not have the same ethical concerns as embryonic stem cells in terms of origin.

References

Lo, B., & Parham, L. (2009, May). Ethical issues in stem cell research. Retrieved December 27,

2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726839/

Orive, G., Hernndez R.M., Gascn A.R., Igartua, M., Luis Pedraz, J. (2003, Mar).

Controversies Over Stem Cell Research. Retrieved December 29, 2020, from https://www.cell.com/trends/biotechnology/fulltext/S0167-7799(03)00003-9

Railton, D. (2019, Feb). Stem cells: Therapy, controversy, and research. (n.d.). Retrieved

December 27, 2020, from https://www.medicalnewstoday.com/articles/200904

Yu, J. and Thomson, J.A. Embryonic Stem Cells. (n.d.). Retrieved December 30, 2020, from

https://stemcells.nih.gov/info/Regenerative_Medicine/2006chapter1.htm

See the original post:
Controversy Over the Use of Embryonic Stem Cells in Research Hadron